PMID- 24798350
OWN - NLM
STAT- MEDLINE
DCOM- 20170509
LR  - 20170509
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 19
IP  - 4
DP  - 2016 Apr
TI  - Good response to infliximab in rheumatoid arthritis following failure of 
      interleukin-1 receptor antagonist.
PG  - 370-6
LID - 10.1111/1756-185X.12387 [doi]
AB  - AIM: To evaluate the efficacy of tumor necrosis factor inhibitor infliximab in 
      patients with rheumatoid arthritis (RA) who were disease-resistant to recombinant 
      human interleukin-1 receptor antagonist (IL-1Ra). METHODS: A total of 104 
      patients with active RA despite methotrexate (MTX) treatment were enrolled in the 
      open trial. Among them, 27 IL-1Ra nonresponders 'Switchers' and 51 biologic-naive 
      patients 'Naivers' received an infusion of 3 mg/kg infliximab at weeks 0, 2, 6 
      and 14, combined with concurrent MTX therapy, while the other 26 patients who had 
      never received any biologics 'Controls' continued MTX monotherapy. Clinical 
      outcomes and safety were assessed at weeks 0, 2 and every 4 weeks thereafter for 
      18 weeks with the American College of Rheumatology (ACR) core set criteria, the 
      Disease Activity Score in 28 joints, and records of adverse events (AEs) and 
      abnormal laboratory findings. RESULTS: At week 18, an ACR20 response was achieved 
      in 56% of Switchers and 61% of Naivers, compared with 23% of Controls (P = 0.0013 
      and 0.0126, respectively). Compared with Controls, both Switchers and Naivers 
      achieved a significant improvement in tender-joint count, swollen-joint count, 
      patient's assessment of pain, patient's and physician's global assessment of 
      disease activity, erythrocyte sedimentation rate and C-reactive protein. 
      Switchers even achieved a greater benefit from health assessment questionnaire 
      (HAQ) scores than Naivers. Infliximab was well tolerated, with a similar 
      incidence of AEs across all study groups. CONCLUSION: Switching from IL-1Ra to 
      infliximab is effective in improving disease activity and maintaining joint 
      function.
CI  - (c) 2014 Asia Pacific League of Associations for Rheumatology and Wiley Publishing 
      Asia Pty Ltd.
FAU - Bao, Jun
AU  - Bao J
AD  - Department of Pediatrics, Xinhua Hospital Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
AD  - Department of Rheumatology & Immunology, Shanghai Changzheng Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - Yue, Tao
AU  - Yue T
AD  - Department of Rheumatology, Shanghai Guanghua Hospital, Shanghai, China.
FAU - Li, Ting
AU  - Li T
AD  - Department of Rheumatology & Immunology, Shanghai Changzheng Hospital, Second 
      Military Medical University, Shanghai, China.
FAU - He, Dong-Yi
AU  - He DY
AD  - Department of Rheumatology, Shanghai Guanghua Hospital, Shanghai, China.
FAU - Bao, Yi-Xiao
AU  - Bao YX
AD  - Department of Pediatrics, Xinhua Hospital Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20140505
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Interleukin 1 Receptor Antagonist Protein)
RN  - B72HH48FLU (Infliximab)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - Adult
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy/immunology
MH  - China
MH  - Double-Blind Method
MH  - Drug Resistance
MH  - *Drug Substitution
MH  - Drug Therapy, Combination
MH  - Female
MH  - Health Status Indicators
MH  - Humans
MH  - Infliximab/adverse effects/*therapeutic use
MH  - Interleukin 1 Receptor Antagonist Protein/adverse effects/*therapeutic use
MH  - Male
MH  - Methotrexate/therapeutic use
MH  - Middle Aged
MH  - Remission Induction
MH  - Severity of Illness Index
MH  - Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Failure
OTO - NOTNLM
OT  - arthritis rheumatoid
OT  - biological agents
OT  - infliximab
OT  - interleukin-1 blocker
OT  - tumor necrosis factor-alpha blocker
EDAT- 2014/05/07 06:00
MHDA- 2017/05/10 06:00
CRDT- 2014/05/07 06:00
PHST- 2014/05/07 06:00 [entrez]
PHST- 2014/05/07 06:00 [pubmed]
PHST- 2017/05/10 06:00 [medline]
AID - 10.1111/1756-185X.12387 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2016 Apr;19(4):370-6. doi: 10.1111/1756-185X.12387. Epub 2014 
      May 5.